KL-003

N/A

Report date: 2024/02/29 20:00:32

Base Information

Drug NameKL-003
Drug Alias NameKL-TH02KL-003KL003
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionHemoglobin beta chain stimulantsGene transference
TargetsHemoglobin beta chain
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKanglin Biotech (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesR&D Kanglin BiotechAffiliated Hospital Of Guangdong Medical UniversityKanglin Biotech (Hangzhou) Co Ltd +[4] 
Inactive CompaniesN/A
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A